PMC

Kaplan–Meier survival analysis for time to anuria in balANZ trial participants over the 2-year study period. The differences between the biocompatible and control groups were statistically significant (P=0.009). Numbers at risk are indicated above the abscissa.

Consolidated Standards of Reporting Trials diagram showing the number of patients recruited into the balANZ study, randomized, followed, and analyzed. APD, automated PD; SAE, serious adverse event; ITT, intention to treat.

Kaplan–Meier survival analysis for time to first peritonitis episode in balANZ trial participants over the 2-year study period. The difference between the biocompatible and control groups was statistically significant (P=0.01). Numbers at risk are indicated above the abscissa.

Nonsignificant difference in residual renal function decline over 2 years in the biocompatible and control groups. (A) The biocompatible group. (B) Controls. Gray lines represent individual patient measurements, whereas solid lines represent predicted slopes in the first and second 12-month follow-up periods. The P value for the three-way interaction of year (first 12 months versus second 12 months) by GFR slope by dialysate was 0.06.